Page 2 - FSANZ Autumn 21 Volume 95 Amended
P. 2
APPROVED
for ART and the prevention of preterm birth*
Proudly
supporting
Australian pregnancies
for 30 years
Natural micronised progesterone pessary
Plant based Vegan
Halal
For more information contact the Perrigo Customer team:
1800 805 546 customerservice@perrigo.com.au
*ORIPRO® is indicated for (1) Assisted reproductive technology (ART) treatment of infertile women with progesterone deficiency, requiring progesterone supplementation or replacement to support embryo implantation and
maintain initial pregnancy, (2) Prevention of preterm birth in singleton pregnancies at risk due to; shortened cervix (midtrimester sonographic cervix ≤25mm) and/or where there is a history of spontaneous preterm birth.
PLEASE REVIEW THE FULL PRODUCT INFORMATION AVAILABLE HERE BEFORE RECOMMENDING.
ORIPRO® is a registered trademark of Orion Laboratories Pty Ltd trading as Perrigo Australia. ABN 56 009 293 136. 25–29 Delawney Street, Balcatta, Western Australia, 6021, AUSTRALIA. https://www.perrigo.com.au. For Medical Information enquiries: 1800 805 546 or Medicalinfo@perrigo.com.au. To report an adverse event: 1800 805 546, https://www.perrigo.com.au/contact/ or via free fax: 1800 004 110. (2103-ORI-061 March 2021)
PBS Information: Authority required (STREAMLINED). For luteal phase support in patients who are receiving medical treatment as described in items 13200 or 13201 of the Medicare Benefits Schedule. The luteal phase is defined as the time span from embryo transfer until implantation confirmed by positive B-hCG measurement. STREAMLINED AUTHORITY CODE 4997.
